Phio Pharmaceuticals Inc. in Marlborough removed the interim tag from Robert Bitterman’s title on Monday, naming him its new president and CEO after he served in the role on a fill-in basis since September.
Marlborough biopharma Phio Pharmaceuticals is ushering in a new strategic plan seeking to reposition the company from pure discovery research to full development, utilizing clinical trials.
/PRNewswire/ Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to.